The Hysteroscopic Morcellator (HM). (HM)
Recruitment status was: Recruiting
The hysteroscopic morcellator (HM) is a novel technique for removal of intrauterine polyps, myomas and placental tissue. It withholds some technical advantages over resectoscopy. Previous data suggest that it's a faster technique than the latter, and shows that it has a low complication rate.
To compare the HM to bipolar resectoscopy for removal of:
1) large intrauterine polyps, 2) smaller type 0 and 1 myomas, 3) residual placental tissue, in terms of efficiency and complications.
Study design: Single blind, randomized controlled multicenter trial.
Study population: Women aged over 18 years old with:
1) large (≥ 1 cm) intrauterine polyps, 2) smaller (≤ 3 cm) type 0 or 1 myomas, 3) residual placental tissue, who are planned for hysteroscopic removal.
Patients are randomized between removal with the HM or the bipolar resectoscope.
Main study parameters/endpoints:
Installation and operating time.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Women who are referred to our polyclinic will be seen on a first visit, and, according to the standard work-up, an ultrasound will be performed when intrauterine pathology is suspected. To confirm the diagnosis a saline infusion sonography (SIS) and/or ambulant diagnostic hysteroscopy will be performed consequently. Once the diagnosis is confirmed and surgery is planned, women will be asked whether they want to take part in this study. At this moment, both techniques are used in our hospitals and the choice of treatment depends on the preference of the gynaecologist. All women will be treated with operative hysteroscopy in a daycare setting according to the standard of care, only now randomized between the two techniques. A standard postoperative visit with ultrasound examination and/or ambulant diagnostic hysteroscopy is scheduled 6 weeks later. Late postoperative complications and complaints are recorded.
It is expected that the HM beholds some advantages over the bipolar resectoscope such as shorter operating time and less complications (e.g. risk of perforation, current and fluid related complications). Previous data do not demonstrate any additional risks related to the use of the HM. Moreover we will check whether the HM has a lower risk of intrauterine adhesion formation, as this might influence patient's fertility.
|Large Intrauterine Polyps Smaller Type 0 and 1 Myomas Residual Placental Tissue||Procedure: Hysteroscopic morcellator Procedure: Resectoscope||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
|Official Title:||The Hysteroscopic Morcellator Versus the Bipolar Resectoscope for Removal of Lager Intrauterine Polyps, Removal of Submucous Myomas and Removal of Residual Placental Tissue: a Randomized Controlled Trial.|
- Installation time and operating time. [ Time Frame: the length of the operation ]
Installation time is defined as the time to set up the hysteroscopic instrumentation ready for use (time from start of setting up the instrumentation to start resection / morcellation).
Operating time is defined as the time starting visual introduction of the hysteroscope until the time at which the procedure is completed and the hysteroscope is removed definitely.
Times will be measured with a stop watch by a trained nurse.
- Check for adhesions during follow-up. [ Time Frame: After 6 weeks, during follow-up visit ]Ambulant diagnostic hysteroscopy is performed at 6 weeks postoperative follow-up.
- Fluid deficit [ Time Frame: during the length of the operation ]Fluid deficit in both procedures is the result of subtracting the outflow volumes from the inflow volumes as measured by the pump.
- complications and complaints [ Time Frame: between operation until 6 weeks follow-up ]
During the postoperative hospital stay blood samples looking for electrolyte imbalances will only be taken when excessive fluid absorption is suspected based on fluid deficit (> 2500 mL for normal saline) and/or clinical symptoms.
At 6 weeks postoperatively a standard visit is scheduled. Complications and complaints are recorded, and ultrasound is performed.
|Study Start Date:||May 2011|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||July 2015 (Final data collection date for primary outcome measure)|
Experimental: hysteroscopic morcellator
Women, randomized into getting a treatment with the hysteroscopic morcellator.
Procedure: Hysteroscopic morcellator
Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
Active Comparator: Resectoscope
Women, randomized into getting a treatment with the resectoscope.
Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01537822
|Contact: Tjalina Hamerlynck, MD||Tjalina.Hamerlynck@ugent.be|
|Contact: Steven Weyers, MD, PhD||Steven.Weyers@ugent.be|
|Ghent University Hospital||Recruiting|
|Ghent, Belgium, 9000|
|Contact: Steven Weyers, MD, PhD Steven.Weyers@ugent.be|
|Principal Investigator: Steven Weyers, MD, PhD|
|Sub-Investigator: Tjalina Hamerlynck, MD|
|Catharina Hospital Eindhoven||Recruiting|
|Eindhoven, Netherlands, 5602 ZA|
|Contact: Benedictus C Schoot, MD, PhD|
|Principal Investigator: Benedictus C Schoot, MD, PhD|
|Sub-Investigator: Tjalina Hamerlynck, MD|
|Sub-Investigator: Viviane Dietz, MD, PhD|
|Principal Investigator:||Steven Weyers, MD, PhD||University Hospital, Ghent|